<DOC>
	<DOCNO>NCT01763164</DOCNO>
	<brief_summary>Two-arm , randomize , prospective , open-label , multi-center , phase III study compare efficacy safety MEK162 ( 45 mg BID ) versus dacarbazine ( 1000 mg/m2 IV every 3 week ) patient advance ( Stage IIIC ) unresectable metastatic ( Stage IV ) NRAS Q61 mutation-positive cutaneous unknown primary melanoma . The mutation analysis perform central laboratory . Only patient Q61 mutation per central laboratory meet eligibility criterion randomize . A total 393 patient randomize 2:1 receive either MEK162 dacarbazine . Patients stratify accord AJCC stage ( IIIC , IVM1a , IVM1b versus IVM1c ) , ECOG Performance status ( 0 versus 1 ) prior number line immunotherapy ( immunotherapy versus none ) . This study use Interactive Response Technology ( IRT ) . The primary end point study progression-free survival . Key secondary end point overall survival</brief_summary>
	<brief_title>Study Comparing Efficacy MEK162 Versus Dacarbazine Unresectable Metastatic NRAS Mutation-positive Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Diagnosis locally advance , unresectable metastatic cutaneous melanoma unknown primary AJCC Stage IIIC IV ( uveal mucosal melanoma exclude ) Presence NRAS Q61 mutation tumor tissue prior randomization determine Novartis designated central laboratory Naïve untreated patient patient progressed number prior line immunotherapy unresectable locally advanced metastatic melanoma Evidence least one measurable lesion detect radiological photographic method Adequate bone marrow , organ function , cardiac laboratory parameter Normal function daily living activity Any untreated CNS metastasis Uveal mucosal melanoma History current evidence retinal vein occlusion ( RVO ) risk factor RVO Patients washout period &lt; 6 week last dose ipilimumab immunotherapy . Previous systemic chemotherapy unresectable locally advanced metastatic melanoma . History Gilbert 's syndrome Prior therapy MEK inhibitor Impaired cardiovascular function clinically significant cardiovascular disease Uncontrolled arterial hypertension despite medical treatment HIV positive active Hepatitis A B Impairment gastrointestinal function Patients undergone major surgery radiotherapy ≤ 3 week prior start study drug recover side effect procedure ; Patients neuromuscular disorder associate elevated CK . Pregnant nursing ( lactate ) woman Medical , psychiatric , cognitive condition may compromise patient 's ability understand patient information , give informed consent , comply study protocol complete study Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Cutaneous melanoma</keyword>
	<keyword>Skin disease</keyword>
	<keyword>Skin cancer</keyword>
	<keyword>Skin Neoplasms</keyword>
	<keyword>Neoplasm Metastasis</keyword>
</DOC>